ACTIVATION OF BCR-ABL FUSION GENE AND RAS ONCOGENES IN CHRONIC MYELOGENOUS LEUKEMIA

被引：4
作者：
FUTAKI, M
INOKUCHI, K
DAN, K
NOMURA, T
机构：
[1] The Third Department of Internal Medicine, Nippon Medical School, Tokyo
来源：
LEUKEMIA & LYMPHOMA | 1991年 / 5卷 / 2-3期
关键词：
CML; PHILADELPHIA CHROMOSOME; BCR-ABL FUSION GENE; TRANSFORMING; GENE; RAS ONCOGENES;
D O I：
10.3109/10428199109068121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We attempted to detect the bcr-abl fusion gene and ras gene family in CML by the in vitro focus forming assay and the tumorigenicity assay. Eight of 14 chronic phase and both of two blastic phase cases showed transforming activity in the tumorigenicity assay. However, only one chronic phase sample was positive in the in vitro focus forming assay. Among these 10 transformants, we found N-ras activation in one chronic phase, and K-ras activation in another chronic phase case. The bcr-abl fusion gene was activated in one chronic phase and all of the blastic phase cases by the tumorigenicity assay. The present result showed that the bcr-abl fusion gene transfected N1H3T3 cells formed tumors in nude mice in contrast to the in vitro focus forming assay. The bcr-abl fusion gene may play important roles in the progression as well as the pathogenesis of CML. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码：163 / 169
页数：7
相关论文
共 20 条
  • [1] Rowley J.D., A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining, Nature, 243, pp. 290-293, (1973)
  • [2] Shtivelman E., Lifshitz B., Gale R.P., Canaani E., Fused transcripts of abl and bcr genes in chronic myelogenous leukaemia, Nature, 315, pp. 550-554, (1985)
  • [3] Krontiris T.G., Cooper G.M., Transforming activity of human tumor DNAs, Proc. Natl. Acad. Sci. USA, 78, pp. 1181-1184, (1981)
  • [4] Hirai H., Tanaka S., Azuma M., Anraku Y., Kobayashi Y., Fujisawa M., Okabe T., Urabe A., Takaku F., Transforming genes in human leukemia cells, Blood, 66, pp. 1371-1378, (1985)
  • [5] Liu E., Hjelle B., Bishop J.M., Transforming genes in chronic myelogenous leukemia, Proc. Natl. Acad. Sci. USA, 85, pp. 1952-1956, (1988)
  • [6] Janssen J.W.G., Steenvoorden A.C.M., Lyons J., Anger B., Bohlke J.U., Bos J.L., Seliger H., Bartram C.R., RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders and myelodys-plastic syndromes, Proc. Natl. Acad. Sci. USA, 84, pp. 9228-9232, (1987)
  • [7] Collins S.J., Howard M., Andrews D.F., Agura E., Radich J., Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia, Blood, 73, pp. 1028-1032, (1989)
  • [8] Daley G.Q., McLaughlin J., Witte O.N., Baltimore D., The CML-specific P210 bcr/abl protein, unlike v-abl does not transform N1H3T3 fibroblasts, Science, 237, pp. 532-535, (1987)
  • [9] Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., Baltimore D., The chronic myelogenous leukemia specific P210 protein is the product of the bcr/abl hybrid gene, Science, 233, pp. 212-214, (1986)
  • [10] Daley G.Q., Van Etten R.A., Baltimore D., Induction of chronic myelogenous leukemia in mice by the P210<sup>ber/abl</sup> gene of the Philadelphia chromosome, Science, 247, pp. 824-830, (1990)
12